Clinical and Microbiological Characteristics of Chryseobacterium indologenes Bacteremia: A 20-Year Experience in a Single University Hospital
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Chryseobacterium indologenes is ubiquitous in nature and rarely causes infections. However, the clinical impact of C. indologenes has increased in recent years, especially in immunocompromised patients, and has resulted in high mortality rates. We aimed to investigate the clinical and microbiological characteristics of C. indologenes bacteremia. Materials and Methods: We retrospectively reviewed medical records of a 642-bed university-affiliated hospital in Korea, dating from January 2001 to December 2020, to investigate C. indologenes bacteremia. Results: A total of 22 C. indologenes isolates were identified from blood culture records. All patients were hospitalized at the time of bacteremia, and the most common manifestation was primary bacteremia. A sizable majority of the patients (83.3%) had underlying diseases, and all patients received intensive care unit care during their admission. The 14-day and 28-day mortality rates were 8.3% and 16.7%, respectively. Importantly, all C. indologenes isolates were 100% susceptible to trimethoprim-sulfamethoxazole. Conclusion: In our study, most of the infections were hospital-acquired, and the susceptibility pattern of the C. indologenes isolates showed multidrug resistance. However, trimethoprim-sulfamethoxazole is a potentially useful antibiotic for C. indologenes bacteremia treatment. More attention is required to identify C. indologenes as one of the most important nosocomial bacteria with detrimental effects in immunocompromised patients.
Abstract
Background: Chryseobacterium indologenes is ubiquitous in nature and rarely causes infections. However, the clinical impact of C. indologenes has increased in recent years, especially in immunocompromised patients, and has resulted in high mortality rates. We aimed to investigate the clinical and microbiological characteristics of C. indologenes bacteremia. Materials and Methods: We retrospectively reviewed medical records of a 642-bed university-affiliated hospital in Korea, dating from January 2001 to December 2020, to investigate C. indologenes bacteremia. Results: A total of 22 C. indologenes isolates were identified from blood culture records. All patients were hospitalized at the time of bacteremia, and the most common manifestation was primary bacteremia. A sizable majority of the patients (83.3%) had underlying diseases, and all patients received intensive care unit care during their admission. The 14-day and 28-day mortality rates were 8.3% and 16.7%, respectively. Importantly, all C. indologenes isolates were 100% susceptible to trimethoprim-sulfamethoxazole. Conclusion: In our study, most of the infections were hospital-acquired, and the susceptibility pattern of the C. indologenes isolates showed multidrug resistance. However, trimethoprim-sulfamethoxazole is a potentially useful antibiotic for C. indologenes bacteremia treatment. More attention is required to identify C. indologenes as one of the most important nosocomial bacteria with detrimental effects in immunocompromised patients.
참고문헌 (28)
- Vandamme P, "New perspectives in the classification of the flavobacteria : sescription of Chryseobacterium gen. nov., Bergeyella gen. nov., and Empedobacter nom. rev", Int J Syst Bacteriol, 44, pp.827~831 (1994)
- Bonten MJ, "Topical antimicrobial prophylaxis of nosocomial pneumonia in mechanically ventilated patients. Microbiological observations", Infection, 21, pp.137~139 (1993)
- Hsueh PR, "Flavobacterium indologenes bacteremia : clinical and microbiological characteristics", Clin Infect Dis, 23, pp.550~555 (1996)
- Izaguirre-Anariba DE, "Chryseobacterium indologenes, an emerging bacteria : a case report and review of literature", Cureus, 12, pp.e6720~ (2020)
- Sud A, "Rare case of meningitis due to an emerging pathogen Chryseobacterium indologenes", SAGE Open Med Case Rep, 8, pp.2050313X20936098~ (2020)
- Lee IJ, "Chryseobacterium indologenes Keratitis : successful treatment of multidrug-resistant strain", Case Rep Ophthalmol Med, 2021, pp.5527775~ (2021)
- Hsueh PR, "Flavobacterium indologenes bacteremia : clinical and microbiological characteristics", Clin Infect Dis, 23, pp.550~555 (1996)
- Nulens E, "Recurrent bacteremia by Chryseobacterium indologenes in an oncology patient with a totally implanted intravascular device", Clin Microbiol Infect, 7, pp.391~393 (2001)
- Green BT, "Cellulitis and bacteraemia due to Chryseobacterium indologenes", J Infect, 42, pp.219~220 (2001)
- Lin JT, "Chryseobacterium indologenes bacteremia in a bone marrow transplant recipient with chronic graft-versus-host disease", Scand J Infect Dis, 35, pp.882~883 (2003)
- Christakis GB, "Chryseobacterium indologenes non-catheter-related bacteremia in a patient with a solid tumor", J Clin Microbiol, 43, pp.2021~2023 (2005)
- Cascio A, "Chryseobacterium indologenes bacteraemia in a diabetic child", J Med Microbiol, 54, pp.677~680 (2005)
- Ray P, "Chryseobacterium indologenes bacteremia : a case report", J Commun Dis, 37, pp.259~260 (2005)
- Akay M, "Catheter-related bacteremia due to Chryseobacterium indologenes in a bone marrow transplant recipient", Bone Marrow Transplant, 37, pp.435~436 (2006)
- Bayraktar MR, "Postoperative Chryseobacterium indologenes bloodstream infection caused by contamination of distillate water", Infect Control Hosp Epidemiol, 28, pp.368~369 (2007)
- Hsueh PR, "Clinical and microbiological characteristics of Flavobacterium indologenes infections associated with indwelling devices", J Clin Microbiol, 34, pp.1908~1913 (1996)
- Agarwal S, "Severe Sepsis Due to Chryseobacterium indologenes, a possible emergent multidrug-resistant organism in intensive care unit-acquired infections", Indian J Crit Care Med, 22, pp.817~819 (2018)
- Kirby JT, "Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp : report from the SENTRY antimicrobial surveillance program(1997-2001)", J Clin Microbiol, 42, pp.445~448 (2004)
- Clinical and Laboratory Standards Institute (CLSI), "Performance standards for antimicrobial susceptibility testing" (2021), CLSI
- Singer M, "The third international consensus definitions for sepsis and septic shock(Sepsis-3)", JAMA, 315, pp.801~810 (2016)
- Bhagawati G, "Bacteremia by Chryseobacterium indologenes in a patient with lung cancer : a clinical and microbiological investigation", Indian J Crit Care Med, 23, pp.157~159 (2019)
- Chen FL, "Clinical and epidemiological features of Chryseobacterium indologenes infections : analysis of 215 cases", J Microbiol Immunol Infect, 46, pp.425~432 (2013)
- Lin YT, "Clinical and microbiological characteristics of Chryseobacterium indologenes bacteremia", J Microbiol Immunol Infect, 43, pp.498~505 (2010)
- Chou DW, "Clinical characteristics, antimicrobial susceptibilities, and outcomes of patients with Chryseobacterium indologenes bacteremia in an intensive care unit", Jpn J Infect Dis, 64, pp.520~524 (2011)
- Chang YC, "Identification, epidemiological relatedness, and biofilm formation of clinical Chryseobacterium indologenes isolates from central Taiwan", J Microbiol Immunol Infect, 48, pp.559~564 (2015)
- Chang YC, "Identification, epidemiological relatedness, and biofilm formation of clinical Chryseobacterium indologenes isolates from central Taiwan", J Microbiol Immunol Infect, 48, pp.559~564 (2015)
- Mukerji R, "Chryseobacterium indologenes : an emerging infection in the USA", BMJ Case Rep, 2016, pp.bcr2016214486~ (2016)
- Kirby JT, "Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp : report from the SENTRY antimicrobial surveillance program(1997-2001)", J Clin Microbiol, 42, pp.445~448 (2004)